Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its prognostic implication and dynamics during chemotherapy in advanced gastric cancer (GC). Materials and Methods We prospectively enrolled 68 GC patients who were candidates for palliative standard first-line chemotherapy, and serially collected blood at baseline and after one cycle of chemotherapy, at the best response and after disease progression. sPDL1 was measured using an enzyme-linked immunosorbent assay. Response to chemotherapy, overall survival (OS), progression-free survival (PFS) and other prognostic factors including neutrophil-lymphocyte ratio (NLR) were obtained. The cut-off value of sPDL1 levels for survival analysis was found using C-statistics. Results The median baseline sPDL1 was 0.8 ng/mL (range, 0.06 to 6.06 ng/mL). The median OS and PFS were 14.9 months and 8.0 months, respectively. sPDL1 and NLR showed a weak positive correlation (Spearman’s rho=0.301, p=0.013). Patients with low levels of sPDL1 at diagnosis (< 1.92 ng/mL) showed a better OS and PFS than patients with a high sPDL1. The baseline sPDL1 before treatment was higher in the progressive disease group than in the stable disease and partial response groups. Patients whose sPDL1 increased after the first cycle of chemotherapy showed worse PFS and OS. Following disease progression, sPDL1 increased compared with the baseline. Conclusion sPDL1 at prechemotherapy confers a prognostic value for PFS and OS in GC patients under palliative first-line chemotherapy. Dynamics of sPDL1 during chemotherapy correlates with disease progression.
Abstract
Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and post-chemotherapy and evaluated its prognostic implication and dynamics during chemotherapy in advanced gastric cancer (GC). Materials and Methods We prospectively enrolled 68 GC patients who were candidates for palliative standard first-line chemotherapy, and serially collected blood at baseline and after one cycle of chemotherapy, at the best response and after disease progression. sPDL1 was measured using an enzyme-linked immunosorbent assay. Response to chemotherapy, overall survival (OS), progression-free survival (PFS) and other prognostic factors including neutrophil-lymphocyte ratio (NLR) were obtained. The cut-off value of sPDL1 levels for survival analysis was found using C-statistics. Results The median baseline sPDL1 was 0.8 ng/mL (range, 0.06 to 6.06 ng/mL). The median OS and PFS were 14.9 months and 8.0 months, respectively. sPDL1 and NLR showed a weak positive correlation (Spearman’s rho=0.301, p=0.013). Patients with low levels of sPDL1 at diagnosis (< 1.92 ng/mL) showed a better OS and PFS than patients with a high sPDL1. The baseline sPDL1 before treatment was higher in the progressive disease group than in the stable disease and partial response groups. Patients whose sPDL1 increased after the first cycle of chemotherapy showed worse PFS and OS. Following disease progression, sPDL1 increased compared with the baseline. Conclusion sPDL1 at prechemotherapy confers a prognostic value for PFS and OS in GC patients under palliative first-line chemotherapy. Dynamics of sPDL1 during chemotherapy correlates with disease progression.
참고문헌 (29)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~86 (2015)
- Corley DA, "Oesophageal and gastric cardia adenocarcinomas : analysis of regional variation using the Cancer Incidence in Five Continents database", Int J Epidemiol, 30, pp.1415~1425 (2001)
- Kim YH, "Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma", Cancer, 85, pp.295~301 (1999)
- Bang YJ, "Docetaxel 75 mg", m(2)is active and well tolerated in patients with metastatic or recurrent gastric cancer : a phase II trial, 2002, pp.32, 248~254
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Fuchs CS, "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial", Lancet, 383, pp.31~39 (2014)
- FDA grants accelerated approval to pembrolizumab for advanced gastric cancer, "U.S. Food and Drug Administration", U.S. Food and Drug Administration, ~ (2018)
- Kang YK, "Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)
- Doi T, "Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma", J Clin Oncol, 36, pp.61~67 (2018)
- Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
- Zhang J, "Circulating PDL1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics", Thorac Cancer, 6, pp.534~538 (2015)
- Finkelmeier F, "High levels of the soluble programmed death-ligand(sPDL1)identify hepatocellular carcinoma patients with a poor prognosis", Eur J Cancer, 59, pp.152~159 (2016)
- Ha H, "Soluble programmed death-ligand 1(sPDL1)and neutrophilto-lymphocyte ratio(NLR)predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy", Oncotarget, 7, pp.76604~76612 (2016)
- Okuma Y, "High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer", Lung Cancer, 104, pp.1~6 (2017)
- Zheng Z, "Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications", Chin J Cancer Res, 26, pp.104~111 (2014)
- Takahashi N, "Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer", J Cancer Res Clin Oncol, 142, pp.1727~1738 (2016)
- Pencina MJ, "Evaluating discrimination of risk prediction models : the C statistic", JAMA, 314, pp.1063~1064 (2015)
- 하혜림, "Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology", Cancer Research and Treatment, 51(2), pp.832~840 (2019), 대한암학회
- Park H, "Prognostic implications of soluble programmed deathligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer", Sci Rep, 9, pp.11131~ (2019)
- Dong H, "Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
- Zhou J, "Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade", Cancer Immunol Res, 5, pp.480~492 (2017)
- Daassi D, "The importance of exosomal PDL1 in tumour immune evasion", Nat Rev Immunol, 20, pp.209~215 (2020)
- Keir ME, "PD-1 and its ligands in tolerance and immunity", Annu Rev Immunol, 26, pp.677~704 (2008)
- Frigola X, "Soluble B7-H1 : differences in production between dendritic cells and T cells", Immunol Lett, 142, pp.78~82 (2012)
- Echizen K, "Inflammation in gastric cancer : interplay of the COX-2", prostaglandin E2 and Toll-like receptor, Cancer Sci, pp.2016, 107[DOI]
- Oh BS, "Prognostic value of C-reactive protein and neutrophilto-lymphocyte ratio in patients with hepatocellular carcinoma", BMC Cancer, 13, pp.78~ (2013)
- Yin Y, "Prognostic value of the neutrophil to lymphocyte ratio in lung cancer : a meta-analysis", Clinics(Sao Paulo), 70, pp.524~530 (2015)
- Haram A, "The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer : a systematic review", J Surg Oncol, 115, pp.470~479 (2017)
- Ock CY, "Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer", Gastric Cancer, 20, pp.254~262 (2017)